WO2007137071A3 - Compositions of r(+) and s(-) pramipexole and methods of using the same - Google Patents

Compositions of r(+) and s(-) pramipexole and methods of using the same Download PDF

Info

Publication number
WO2007137071A3
WO2007137071A3 PCT/US2007/069044 US2007069044W WO2007137071A3 WO 2007137071 A3 WO2007137071 A3 WO 2007137071A3 US 2007069044 W US2007069044 W US 2007069044W WO 2007137071 A3 WO2007137071 A3 WO 2007137071A3
Authority
WO
WIPO (PCT)
Prior art keywords
pramipexole
compositions
methods
same
parkinson
Prior art date
Application number
PCT/US2007/069044
Other languages
French (fr)
Other versions
WO2007137071A2 (en
Inventor
Michael E Bozik
Thomas Petzinger Jr
Valentin Gribkoff
Original Assignee
Knopp Neurosciences Inc
Michael E Bozik
Thomas Petzinger Jr
Valentin Gribkoff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/733,642 external-priority patent/US20070259930A1/en
Priority to CN2007800179185A priority Critical patent/CN101448498B/en
Priority to AU2007253899A priority patent/AU2007253899A1/en
Priority to ES07797504T priority patent/ES2379117T3/en
Priority to EP07797504A priority patent/EP2026803B1/en
Priority to JP2009511221A priority patent/JP2009537565A/en
Application filed by Knopp Neurosciences Inc, Michael E Bozik, Thomas Petzinger Jr, Valentin Gribkoff filed Critical Knopp Neurosciences Inc
Priority to DK07797504.3T priority patent/DK2026803T3/en
Priority to PL07797504T priority patent/PL2026803T3/en
Priority to CA002652251A priority patent/CA2652251A1/en
Priority to AT07797504T priority patent/ATE537826T1/en
Publication of WO2007137071A2 publication Critical patent/WO2007137071A2/en
Publication of WO2007137071A3 publication Critical patent/WO2007137071A3/en
Priority to IL195256A priority patent/IL195256A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Tires In General (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Compositions of predetermined amounts of R(+) pramipexole and S(-) pramipexole and methods of using the same, including for the treatment and prevention of Parkinson's disease, are provided.
PCT/US2007/069044 2006-05-16 2007-05-16 Compositions of r(+) and s(-) pramipexole and methods of using the same WO2007137071A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AT07797504T ATE537826T1 (en) 2006-05-16 2007-05-16 COMPOSITIONS OF R(+)- AND S(-)-PRAMIPEXOLE AND METHOD FOR THEIR USE
AU2007253899A AU2007253899A1 (en) 2006-05-16 2007-05-16 Compositions of R(+) and S(-) pramipexole and methods of using the same
ES07797504T ES2379117T3 (en) 2006-05-16 2007-05-16 Compositions of R (+) and S (-) pramipexole and methods of use thereof
EP07797504A EP2026803B1 (en) 2006-05-16 2007-05-16 Compositions of r(+) and s(-) pramipexole and methods of using the same
JP2009511221A JP2009537565A (en) 2006-05-16 2007-05-16 R (+) and S (-) pramipexole compositions and methods of using the same
CN2007800179185A CN101448498B (en) 2006-05-16 2007-05-16 Compositions of r(+) and s(-) pramipexole and methods of using the same
DK07797504.3T DK2026803T3 (en) 2006-05-16 2007-05-16 Compositions of R (+) and S (-) pramipexole and methods for their use
PL07797504T PL2026803T3 (en) 2006-05-16 2007-05-16 Compositions of r(+) and s(-) pramipexole and methods of using the same
CA002652251A CA2652251A1 (en) 2006-05-16 2007-05-16 Compositions of r(+) and s(-) pramipexole and methods for using the same
IL195256A IL195256A0 (en) 2006-05-16 2008-11-12 Compositions of r(+)and s(-)pramipexole and methods of using the same

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US74732006P 2006-05-16 2006-05-16
US60/747,320 2006-05-16
US87000906P 2006-12-14 2006-12-14
US60/870,009 2006-12-14
US89482907P 2007-03-14 2007-03-14
US89483507P 2007-03-14 2007-03-14
US89479907P 2007-03-14 2007-03-14
US60/894,835 2007-03-14
US60/894,799 2007-03-14
US60/894,829 2007-03-14
US11/733,642 2007-04-10
US11/733,642 US20070259930A1 (en) 2006-04-10 2007-04-10 Compositions and methods of using r(+) pramipexole

Publications (2)

Publication Number Publication Date
WO2007137071A2 WO2007137071A2 (en) 2007-11-29
WO2007137071A3 true WO2007137071A3 (en) 2008-04-17

Family

ID=40134109

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/069044 WO2007137071A2 (en) 2006-05-16 2007-05-16 Compositions of r(+) and s(-) pramipexole and methods of using the same

Country Status (13)

Country Link
US (3) US8017598B2 (en)
EP (1) EP2026803B1 (en)
JP (1) JP2009537565A (en)
KR (1) KR20090021169A (en)
CN (2) CN101448498B (en)
AT (1) ATE537826T1 (en)
AU (1) AU2007253899A1 (en)
CA (1) CA2652251A1 (en)
DK (1) DK2026803T3 (en)
ES (1) ES2379117T3 (en)
IL (1) IL195256A0 (en)
PL (1) PL2026803T3 (en)
WO (1) WO2007137071A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007121188A2 (en) * 2006-04-10 2007-10-25 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ATE537826T1 (en) 2006-05-16 2012-01-15 Knopp Neurosciences Inc COMPOSITIONS OF R(+)- AND S(-)-PRAMIPEXOLE AND METHOD FOR THEIR USE
EP2465500A1 (en) * 2006-05-16 2012-06-20 Knopp Neurosciences, Inc. Therapeutically effective amounts of R(+) and S(-) pramipexole for use in the treatment of parkinson's disease
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CA2681110A1 (en) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
AU2008224869A1 (en) * 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
WO2009109990A2 (en) * 2008-01-24 2009-09-11 Sun Pharmaceutical Industries Ltd. Pharmaceutical composition of pramipexole
PT2303330T (en) * 2008-06-06 2018-02-12 Pharma Two B Ltd Pharmaceutical compositions for treatment of parkinson's disease
JP2012500283A (en) 2008-08-19 2012-01-05 ノップ ニューロサイエンシーズ、インク． (R) -Composition and method using pramipexole
WO2010115267A1 (en) * 2009-04-09 2010-10-14 Purdue Pharma Once-daily oral ir/cr pramipexole formulation
BRPI1010084A2 (en) * 2009-06-19 2015-08-25 Knopp Neurosciences Inc Method to Treat Amyotrophic Lateral Sclerosis in a Patient
US20120059013A1 (en) * 2010-03-09 2012-03-08 Boehringer Ingelheim International Gmbh Method of treating early morning akinesia in subjects having parkinson's disease
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
DK3019167T3 (en) 2013-07-12 2021-03-15 Knopp Biosciences Llc TREATMENT OF ELEVATED LEVELS OF EOSINOPHILES AND / OR BASOPHILES
AU2014306683B2 (en) 2013-08-13 2017-10-12 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
DK3033081T3 (en) 2013-08-13 2021-05-31 Knopp Biosciences Llc Compositions and methods of treatment of chronic urticaria
EP2870965A1 (en) * 2013-11-06 2015-05-13 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical formulations of pramipexole
AU2018243718A1 (en) 2017-03-27 2019-11-07 Chase Therapeutics Corporation Compositions and methods for treating synucleinopathies
KR20200002899A (en) 2017-04-10 2020-01-08 체이스 테라퓨틱스 코포레이션 NK1-antagonist combinations and methods for treating synuclein lesions
MA52457A (en) * 2017-04-13 2021-03-10 Chase Therapeutics Corp PHARMACEUTICAL COMBINATION AND ITS USE FOR THE TREATMENT OF SYNUCLEINOPATHIES
CN111588692B (en) * 2020-05-23 2022-11-22 常州市第四制药厂有限公司 Pramipexole dihydrochloride oral solution
CN115260119B (en) * 2022-07-26 2023-02-10 山东京卫制药有限公司 Pramipexole xinafoate and drug sustained release preparation thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003049705A2 (en) * 2001-12-11 2003-06-19 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
WO2006015944A2 (en) * 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
WO2007090882A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US4144317A (en) 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4286592A (en) 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4314557A (en) 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4395859A (en) 1980-06-05 1983-08-02 State Of Illinois, Department Of Transportation Method and apparatus for securing an object to a support structure
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4849226A (en) 1981-06-29 1989-07-18 Alza Corporation Method for increasing oxygen supply by administering vasodilator
US4725272A (en) 1981-06-29 1988-02-16 Alza Corporation Novel bandage for administering beneficial drug
US4435180A (en) 1982-05-25 1984-03-06 Alza Corporation Elastomeric active agent delivery system and method of use
US4559222A (en) 1983-05-04 1985-12-17 Alza Corporation Matrix composition for transdermal therapeutic system
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4704282A (en) 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
US4588580B2 (en) 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4573995A (en) 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
DE3572485D1 (en) * 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4645502A (en) 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
US4904475A (en) 1985-05-03 1990-02-27 Alza Corporation Transdermal delivery of drugs from an aqueous reservoir
US4698062A (en) 1985-10-30 1987-10-06 Alza Corporation Medical device for pulsatile transdermal delivery of biologically active agents
DE3775830D1 (en) 1986-06-13 1992-02-20 Alza Corp ACTIVATING A TRANSDERMAL DRUG DELIVERY SYSTEM THROUGH MOISTURE.
US4938759A (en) 1986-09-02 1990-07-03 Alza Corporation Transdermal delivery device having a rate controlling adhesive
US4908027A (en) 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US5344656A (en) 1986-09-12 1994-09-06 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US4788062A (en) 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US5071656A (en) 1987-03-05 1991-12-10 Alza Corporation Delayed onset transdermal delivery device
US4943435A (en) 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4917895A (en) 1987-11-02 1990-04-17 Alza Corporation Transdermal drug delivery device
US4781924A (en) 1987-11-09 1988-11-01 Alza Corporation Transdermal drug delivery device
US5004610A (en) 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
DE69009540T2 (en) 1989-03-15 1994-09-29 Nitto Denko Corp Adhesive plasters containing medicines.
US5591454A (en) 1989-09-05 1997-01-07 Alza Corporation Method for lowering blood glucose
US5091190A (en) 1989-09-05 1992-02-25 Alza Corporation Delivery system for administration blood-glucose lowering drug
US5024843A (en) 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
DE3937271A1 (en) 1989-11-09 1991-05-16 Boehringer Ingelheim Kg TRANSDERMAL APPLICATION OF 2-AMINO-6-N-PROPYLAMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOLE
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5314694A (en) 1990-10-29 1994-05-24 Alza Corporation Transdermal formulations, methods and devices
US5122382A (en) 1990-10-29 1992-06-16 Alza Corporation Transdermal contraceptive formulations, methods and devices
FR2688138B1 (en) 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa APPLICATION OF AMINO-2 TRIFLUOROMETHOXY-6 BENZOTHIAZOLE TO OBTAIN A MEDICINE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS.
WO1993023025A1 (en) 1992-05-13 1993-11-25 Alza Corporation Transdermal administration of oxybutynin
US5792664A (en) 1992-05-29 1998-08-11 The Rockefeller University Methods for producing and analyzing biopolymer ladders
JP3639594B2 (en) 1993-05-28 2005-04-20 ベイラー カレッジ オブ メディシン Method and apparatus for desorption and ionization of analytes
US5442117A (en) 1993-12-13 1995-08-15 Albemarle Corporation Enantiomeric resolution
US5635203A (en) 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
US6156777A (en) 1994-12-15 2000-12-05 Pharmacia & Upjohn Company Use of pramipexole as a neuroprotective agent
US5650420A (en) * 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
US5912268A (en) 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US6262115B1 (en) 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5674895A (en) 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
SI0866704T1 (en) 1995-10-26 2001-08-31 Sanofi Synthelabo Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
GB9705428D0 (en) 1997-03-15 1997-04-30 Knoll Ag Therapeutic agents
US5804215A (en) 1997-03-21 1998-09-08 L. Perrigo Company Transdermal patch disposal system and method
US6294790B1 (en) 1997-09-23 2001-09-25 Ciphergen Biosystems, Inc. Secondary ion generator detector for time-of-flight mass spectrometry
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
PE20000728A1 (en) 1998-06-26 2000-08-21 Cocensys Inc HETEROCYCLES 4-BENZYL PIPERIDINE ALKYLSULFOXIDE AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS
DE19830201A1 (en) 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Antidepressant
WO2000006162A1 (en) 1998-07-27 2000-02-10 Boehringer Ingelheim Pharma Kg Agents with antidepressant action, containing pramipexol and a further antidepressant
US6322819B1 (en) 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
CN100444830C (en) 1998-11-02 2008-12-24 伊兰公司，Plc Multiparticulate modified release composition
US6776984B1 (en) 1999-08-20 2004-08-17 George R. Schwartz Induced regeneration and repair of damaged neurons and nerve axon myelin
WO2000075117A1 (en) 1999-06-04 2000-12-14 Elan Pharma International Ltd. Compositions and methods for inhibiting cell death
DE19938825A1 (en) 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Active ingredient combination with clonidine
US6480820B1 (en) 1999-09-20 2002-11-12 Advanced Cochlear Systems, Inc. Method of processing auditory data
US6750235B1 (en) 1999-09-30 2004-06-15 The General Hospital Corporation Pramipexole as a treatment for cocaine craving
WO2001022820A1 (en) 1999-09-30 2001-04-05 The General Hospital Corporation Use of pramipexole as a treatment for cocaine craving
US6443976B1 (en) 1999-11-30 2002-09-03 Akorn, Inc. Methods for treating conditions and illnesses associated with abnormal vasculature
EP1257560A4 (en) 2000-02-01 2003-10-01 Human Genome Sciences Inc Bcl-2-like polynucleotides, polypeptides, and antibodies
PE20011074A1 (en) 2000-02-23 2001-10-04 Upjohn Co USE OF PRAMIPEXOL IN THE TREATMENT OF ADDICTION DISORDERS
EP1285092A4 (en) 2000-04-14 2003-07-16 Metabolon Inc Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
EP1303502A2 (en) 2000-07-06 2003-04-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Tetrahydrobenzothiazole analogues as neuroprotective agents
DE10037619A1 (en) 2000-08-02 2002-02-14 Daimler Chrysler Ag Arrangement of controls
ES2187249B1 (en) 2000-09-18 2004-09-16 Synthon Bv PROCEDURE FOR THE PREPARATION OF 2-AMINO-6- (RENT) AMINO-4,5,6,7-TETRAHYDROBENZOTIAZOLES.
US20020151526A1 (en) 2000-10-06 2002-10-17 Gallop Mark A. Bile-acid prodrugs of L-dopa and their use in the sustained treatment of parkinsonism
US6618138B2 (en) 2000-10-12 2003-09-09 Jed Khoury Scanning fluorescent systems for various diagnostic
EP1337845B1 (en) 2000-11-16 2012-01-04 Bio-Rad Laboratories, Inc. Method for analyzing mass spectra
US20020177626A1 (en) 2001-01-19 2002-11-28 Cook Graham D. Treatment of sleep disturbances
MXPA03009185A (en) 2001-04-09 2004-02-17 Neurosearch As Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson s disease.
US20030013120A1 (en) 2001-07-12 2003-01-16 Patz Edward F. System and method for differential protein expression and a diagnostic biomarker discovery system and method using same
GB0117618D0 (en) 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
DE10137082A1 (en) 2001-07-28 2003-02-13 Hexal Ag Stable transdermal therapeutic system containing pramipexol or ropinirol, especially for treating Parkinson's disease, comprises backing, drug-containing pressure-sensitive adhesive matrix and protective layers
US20060281797A1 (en) 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
MY139056A (en) 2001-12-28 2009-08-28 Ab Enzymes Gmbh Microbially-expressed thermotolerant phytase for animal feed
DK2260833T3 (en) 2002-01-16 2013-01-07 Boehringer Ingelheim Pharma Two-layer pharmaceutical tablet comprising telmisartan and a diuretic
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
EP1485078B1 (en) 2002-03-15 2012-09-26 Cypress Bioscience, Inc. Milnacipran for the treatment of irritable bowel syndrome
WO2003087834A2 (en) 2002-04-08 2003-10-23 Affinium Pharmaceuticals, Inc. High throughput analysis of recombinant proteins in multi-well plates
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
PA8578501A1 (en) 2002-07-25 2005-02-04 Pharmacia Corp DOSAGE FORM ONCE A DAY OF PRAMIPEXOL
US20050074865A1 (en) 2002-08-27 2005-04-07 Compound Therapeutics, Inc. Adzymes and uses thereof
GB0221513D0 (en) 2002-09-17 2002-10-23 Generics Uk Ltd Novel compounds and processes
US20040132826A1 (en) 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
GB2394951A (en) 2002-11-04 2004-05-12 Cipla Ltd One pot synthesis of 2,6-diamino-4,5,6,7-tetrahydro-benzothiazole
AU2003298837A1 (en) 2002-12-02 2004-06-23 Massachusetts Institute Of Technology Prolonged suppression of electrical activity in excitable tissues
PT1610791E (en) 2003-03-31 2011-05-23 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of dopamine agonist
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US7662987B2 (en) 2003-07-15 2010-02-16 Xenoport, Inc. Methods for synthesis of acyloxyalkyl compounds
DE10333393A1 (en) * 2003-07-23 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system with the active ingredient pramipexole
US7365086B2 (en) 2003-07-25 2008-04-29 Synthon Ip Inc. Pramipexole acid addition salts
US20080020028A1 (en) 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
US20050053649A1 (en) 2003-09-08 2005-03-10 Anne-Marie Chalmers Medication delivery device
AU2004286240A1 (en) 2003-10-23 2005-05-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Biomarkers for amyotrophic lateral sclerosis
ATE496036T1 (en) 2004-03-19 2011-02-15 Dipharma Francis Srl INTERMEDIATE PRODUCTS FOR THE PRODUCTION OF PRAMIPEXOLE
US20050220877A1 (en) 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
CA2562004A1 (en) * 2004-04-06 2005-10-20 University Of Saskatchewan Sinapic acid supplementation
US7539203B2 (en) 2004-05-26 2009-05-26 Intel Corporation Multiple channel flow control with first-in-first-out (FIFO) read/write random access memory (RAM)
WO2006003471A2 (en) 2004-07-03 2006-01-12 Generics [Uk] Limited Process for the preparation of pramipexole by chiral chromatography
EP1778201B1 (en) 2004-08-13 2014-07-16 Boehringer Ingelheim International GmbH Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
DE102004044578A1 (en) 2004-09-13 2006-03-30 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system with an adhesive layer, method for siliconizing a backing layer of the system and use of the backing layer
US20060069263A1 (en) 2004-09-30 2006-03-30 Irina Gribun Process for the reduction of (S)-2-amino-6-propionamido-4,5,6,7-tetrahydrobenzo-thiazole
WO2006048208A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and amlodipine
WO2006060799A2 (en) 2004-12-02 2006-06-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Protein biomarkers and therapeutic targets in an animal model for amyotrophic lateral sclerosis
WO2006071469A2 (en) 2004-12-02 2006-07-06 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Modulation of the neuroendocrine system as a therapy for amyotrophic lateral sclerosis
WO2006070406A1 (en) 2004-12-29 2006-07-06 J.B. Chemicals & Pharmaceuticals Ltd Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
DE112005003227T5 (en) 2004-12-30 2007-11-15 Chemagis Ltd. A new process for the preparation of pramipexole and the mixture of its optical isomers by reduction with sodium triacetoxyborohydride
WO2006119295A2 (en) 2005-05-02 2006-11-09 Combinatorx, Incorporated Compositions and methods for the treatment of neurodegenerative diseases
ES2264378B1 (en) 2005-05-09 2007-11-01 Ragactives, S.L. PROCEDURE FOR THE RESOLUTION OF 2-AMINO-6PROPILAMINO-4,5,6,7-TETRAHYDROBENZOTIAZOL AND INTERMEDIATE COMPOUNDS.
DE602006009670D1 (en) 2005-08-15 2009-11-19 Univ Virginia NEURORESTAURATION WITH R (+) PRAMIPEXOL
WO2007022501A2 (en) 2005-08-18 2007-02-22 Microbia, Inc. Useful indole compounds
WO2007046347A1 (en) 2005-10-18 2007-04-26 Ono Pharmaceutical Co., Ltd. Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis
PL378587A1 (en) 2005-12-29 2007-07-09 Instytut Farmaceutyczny Methods of (S)-(-)-2-amino-6-n-propyloamino-4,5,6,7-tetrahydrobenzotiazole and/or its salts
WO2007121188A2 (en) 2006-04-10 2007-10-25 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ATE537826T1 (en) 2006-05-16 2012-01-15 Knopp Neurosciences Inc COMPOSITIONS OF R(+)- AND S(-)-PRAMIPEXOLE AND METHOD FOR THEIR USE
EP2465500A1 (en) 2006-05-16 2012-06-20 Knopp Neurosciences, Inc. Therapeutically effective amounts of R(+) and S(-) pramipexole for use in the treatment of parkinson's disease
US7675228B2 (en) * 2006-06-14 2010-03-09 E.I. Du Pont De Nemours And Company Electroluminescent iridium compounds with silylated, germanylated, and stannylated ligands, and devices made with such compounds
EP2056795A2 (en) 2006-08-24 2009-05-13 Boehringer Ingelheim Pharma GmbH & Co. KG Process for preparing pramipexole dihydrochloride tablets with high storage stability
US20080081041A1 (en) 2006-09-29 2008-04-03 Jeffrey Nemeth Method of Using IL6 Antagonists with Mitoxantrone for Prostate Cancer
ES2611314T3 (en) 2006-12-14 2017-05-08 Knopp Biosciences Llc Compositions and procedures for using (R) -pramipexole
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
WO2008104847A2 (en) 2007-02-26 2008-09-04 Wockhardt Research Centre Processes for the preparation of pramipexole and salts thereof
CA2681110A1 (en) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
AU2008224869A1 (en) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
RU2470635C2 (en) 2007-05-11 2012-12-27 Сантен Фармасьютикал Ко., Лтд. Preventive and therapeutic agent for posterior eye diseases
JP2012500283A (en) 2008-08-19 2012-01-05 ノップ ニューロサイエンシーズ、インク． (R) -Composition and method using pramipexole
BRPI1010084A2 (en) 2009-06-19 2015-08-25 Knopp Neurosciences Inc Method to Treat Amyotrophic Lateral Sclerosis in a Patient
US20130273557A1 (en) 2010-05-26 2013-10-17 Valentin Gribkoff Compounds and methods of modulating mitochondrial bioenergetic efficiency through an interaction with atp synthase (complex v) and its subunits

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003049705A2 (en) * 2001-12-11 2003-06-19 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
WO2006015944A2 (en) * 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
WO2007090882A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole

Also Published As

Publication number Publication date
US20110293718A1 (en) 2011-12-01
US20130230569A1 (en) 2013-09-05
EP2026803A2 (en) 2009-02-25
JP2009537565A (en) 2009-10-29
US20080014259A1 (en) 2008-01-17
CN101448498A (en) 2009-06-03
US8017598B2 (en) 2011-09-13
ES2379117T3 (en) 2012-04-20
KR20090021169A (en) 2009-02-27
ATE537826T1 (en) 2012-01-15
PL2026803T3 (en) 2012-05-31
EP2026803B1 (en) 2011-12-21
CA2652251A1 (en) 2007-11-29
IL195256A0 (en) 2009-08-03
DK2026803T3 (en) 2012-04-16
CN101448498B (en) 2011-04-27
AU2007253899A1 (en) 2007-11-29
US8445474B2 (en) 2013-05-21
WO2007137071A2 (en) 2007-11-29
CN102160865A (en) 2011-08-24

Similar Documents

Publication Publication Date Title
WO2007137071A3 (en) Compositions of r(+) and s(-) pramipexole and methods of using the same
IL233634A0 (en) Methods, compositions, and kits for the treatment of medical conditions
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
WO2006086562A3 (en) Phenylazetidinone derivatives
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
WO2007109236A8 (en) Microrna fingerprints during human megakaryocytopoiesis
WO2007120980A3 (en) 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
EP1868628A4 (en) Compounds, compositions and methods for the treatment of poxvirus infections
HK1166983A1 (en) Solid forms comprising compounds for the treatment of diseases or disorders, compositions thereof, and use therewith
GB0718905D0 (en) Methods, compositions and formulations for the treatment of thyroid eye disease
WO2008027600A3 (en) Imatinib compositions
WO2007056366A3 (en) Compounds and compositions as ppar modulators
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2008112898A3 (en) Genetic alterations on chromosome 12 and methods of use thereof for the diagnosis and treatment of type 1 diabetes
WO2009015369A3 (en) Isophthalamide derivatives inhibiting beta-secretase activity
EP1670894B8 (en) Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
WO2006080043A3 (en) Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation
WO2006020430A8 (en) Novel composition and methods for the treatment of immune related disease
WO2006019978A3 (en) Compositions and methods for diagnosis and treatment of epilepsy
WO2005112923A3 (en) 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
WO2007048034A3 (en) Use of androgens for the treatment of parkinson' s disease
WO2006094134A3 (en) Kim-1 antibodies for treatment of th2-mediated conditions
WO2006078336A3 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2011008675A3 (en) Catecholamine compounds, compositions, and formulations, and methods of using the same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780017918.5

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2007253899

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2652251

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009511221

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007797504

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007253899

Country of ref document: AU

Date of ref document: 20070516

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020087030672

Country of ref document: KR